BioTheryX secures $92M to advance protein degradation oncology pipeline

By The Science Advisory Board staff writers

May 20, 2021 -- BioTheryX announced it has secured $92 million in series E financing to advance multiple molecular glues, PHM-based proteolysis-targeting chimeras (PROTACs), and monovalent degraders toward clinical development.

The funding was led by Farallon Capital Management. The company reported it plans to bring its first molecular glue program, BTX-1188, into the clinic by the end of 2021, and expand its platform of molecular glues, PROTACs, and monovalent degraders.

In addition, the company plans to advance the clinical development of its lead multikinase inhibitor, BTX-A51, for the treatment of acute myeloid leukemia, myelodysplastic syndromes, and solid tumors.


Copyright © 2021 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.